Innovus announced the launch of AllerVarx™, a new dietary supplement indicated for the relief of allergy symptoms.
AllerVarx bilayer tablets utilize a technology that allows for a controlled release of the ingredients. The fast-release layer provides antihistaminic activity from Perilla dry extract and the sustained-release layer provides anti-allergic activity by boosting Quercetin and vitamin D3 bioavailability via its lipidic matrix.
Perilla dry extract works by mediating the inhibition of the release of histamine and expression of interleukins (IL-6, TNF-alpha). Quercetin works by preventing the recruitment of mast cells by inhibiting cytokines and chemokines (IL-8, ICAM-1). Vitamin D3 exerts an anti-inflammatory effect on mast cell function and supports the normal function of the immune system.
AllerVarx was evaluated for the reduction of nasal and ocular symptoms in patients with allergic rhinitis as well as its impact on the daily use of anti-allergic medications over 30 days. In the clinical trial, AllerVarx decreased total symptom scores by ~70% and decreased the use of anti-allergic meds by ~73%. There was a highly significant decrease (P <.0001) in each symptom (sneezing, rhinorrhea, nasal obstruction, ocular itching, lacrimation, congestion of the conjunctiva) vs. baseline. No adverse effects were observed while taking AllerVarx and all the patients exhibited good compliance.
AllerVarx tablets are supplied in 60-count bottles. It can be purchased directly from the product website.
This article originally appeared on MPR